Green Alpha Advisors LLC Acquires New Stake in Tempus AI, Inc. (NASDAQ:TEM)

Green Alpha Advisors LLC acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 32,283 shares of the company’s stock, valued at approximately $1,090,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Kovitz Investment Group Partners LLC bought a new position in shares of Tempus AI in the third quarter worth about $1,367,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the period. Captrust Financial Advisors bought a new position in Tempus AI in the 3rd quarter worth about $2,726,000. Dakota Wealth Management purchased a new position in shares of Tempus AI during the third quarter worth approximately $1,185,000. Finally, Sigma Planning Corp bought a new stake in shares of Tempus AI during the third quarter valued at approximately $1,323,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TEM. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America increased their price target on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Loop Capital lifted their price objective on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Piper Sandler reiterated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $56.00.

Insider Buying and Selling

In other news, COO Ryan Fukushima sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the transaction, the chief operating officer now directly owns 982,442 shares in the company, valued at $38,914,527.62. This trade represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This trade represents a 2.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 865,041 shares of company stock worth $35,917,673 in the last three months.

Tempus AI Stock Performance

Shares of TEM stock opened at $37.52 on Monday. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock’s 50-day simple moving average is $48.28 and its 200-day simple moving average is $47.27.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.